Additional safety risk to exceptionally approved drugs in Europe?
AIMS Regulatory requirements for new drugs have increased. Special approval procedures with priority assessment are possible for drugs with clear 'unmet medical need'. We question whether these Exceptional Circumstances (EC) or Conditional Approval (CA) procedures have led to a higher probability of serious safety issues. METHODS A retrospective cohort study was performed of new drugs approved in Europe between 1999 and 2009. The determinant was EC/CA vs. standard procedure approval. Outcome variables were frequency and timing of a first Direct Healthcare Professional Communication (DHPC). An... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2011 |
Reihe/Periodikum: | Arnardottir , A H , Haaijer-Ruskamp , F M , Straus , S M J , Eichler , H-G , de Graeff , P A & Mol , P G M 2011 , ' Additional safety risk to exceptionally approved drugs in Europe? ' , British Journal of Clinical Pharmacology , vol. 72 , no. 3 , pp. 490-499 . https://doi.org/10.1111/j.1365-2125.2011.03995.x |
Schlagwörter: | conditional approval / drug safety / exceptional circumstances / licensing of drugs / regulatory affairs / REGULATORY ACTIONS / HEALTH-CARE / NETHERLANDS / INNOVATION / BENEFIT / ACCESS |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-27600151 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://hdl.handle.net/11370/2b7d7250-94e7-4874-a40a-3bb1fa914cd1 |